Isolated central nervous system relapse of systemic lymphoma (SCNSL): Clinical features and outcome of a retrospective analysis;Isoliertes zentralnervensystem-rezidiv eines systemischen lymphoms: Klinische merkmale und verlauf einer retrospektiven analyse

GMS German Medical Science

Volumn 9, Issue , 2011, Pages

  Patrij, Katrin ^a   Reiser, Marcel ^b   Wätzel, Luise ^b   Pels, Hendrik ^c   Kowoll, Annika ^d   Herrlinger, Ulrich ^a   Engert, Andreas ^b   Linnebank, Michael ^a   Schackert, Gabriele ^e   Vogt Schaden, Marlies ^f   Egerer, Gerlinde ^f   Lamprecht, Monika ^g   Batchelor, Tracy T ^h   Schlegel, Uwe ^c   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Department of Vascular Surgery   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; CNS; Lymphoma; Methotrexate; Neoplasia; Relapse

Indexed keywords

EID: 79959447998     PISSN: 16123174     EISSN: None     Source Type: Journal    
DOI: 10.3205/000134     Document Type: Article

References (17)

1. Van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008;49 Suppl 1:52-58. DOI: 10.1080/10428190802311458
2. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-4495. DOI: 10.1200/JCO.2003.04.056
3. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13(7):1099-1107. DOI: 10.1093/annonc/mdf175
4. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85(1):45-50. DOI: 10.1007/s00277-005-1096-3
5. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. Acta Oncol. 1996;35(6):703-8. DOI: 10.3109/02841869609084002
6. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, A-Tjak RV, Charvat MV, Kluin-Nelemans JC. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol. 1997;54(7):854-859.
7. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Brière J, Reyes F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000;11(6):685-690. DOI: 10.1023/A:1008394827806
8. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284-4289. DOI: 10.1182/blood-2003-02-0542
9. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-133. DOI: 10.1093/annonc/mdh013
10. Van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997;8(6):515-24. DOI: 10.1023/A:1008248315859
11. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043. DOI: 10.1200/JCO.2005.13.524
12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-80.
13. World Health Organization. WHO Handbook for Reporting results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. p. 14-21. (WHO offset publication; no. 48). Available from: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf
14. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541-545. DOI: 10.1093/annonc/mdl434
15. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157. DOI: 10.1093/annonc/mdl327
16. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-1093. DOI: 10.1182/blood-2007-07-101402
17. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-119. DOI: 10.1200/JCO.2008.16.8021